Article

FDG-PET/CT for diagnosis of primary ovarian cancer.

Department of PET Diagnosis, Institute of Biomedical Research and Innovation, 2-2 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047 Japan.
Nuclear Medicine Communications (Impact Factor: 1.38). 03/2011; 32(7):549-53. DOI: 10.1097/MNM.0b013e328345b339
Source: PubMed

ABSTRACT To evaluate the diagnostic value of integrated 18F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT) to discriminate malignant from benign ovarian tumors.
One hundred and eight women suspected of having ovarian cancer underwent preoperative FDG-PET/CT scans. FDG uptake was quantified by calculating the maximum standardized uptake value (SUV max) of each tumor. The receiver operating characteristic curve was drawn to determine the optimal cut-off values of SUV max that would best discriminate between benign and malignant tumors. Histopathologic results served as the reference standard. We assessed the association between SUV max and with International Federation of Gynecology and Obstetrics stage in borderline and malignant tumors, using one-factor analysis of variance and an unpaired t test with Bonferoni correction.
The SUV max of benign (n=26), borderline (n=12) and malignant (n=73) lesions was 2.00 ± 1.02, 2.72 ± 1.04, and 7.55 ± 4.29, respectively. Although there were significant differences between benign and malignant, and borderline and malignant lesions (P<0.0001), there was no significant difference between benign and borderline lesions. Using an SUV max cutoff of 2.55, the sensitivity, specificity and accuracy of FDG-PET/CT scanning to detect malignant or borderline tumors were 82.4, 76.9, and 81.1%, respectively. The SUV max of stage I (n=35), stage II (n=8), stage III (n=34) and stage IV (n=8) was 3.59 ± 2.32, 5.18 ± 1.34, 8.72 ± 2.69, and 15.05 ± 3.77, respectively, and significant differences were observed between SUV max values and the various International Federation of Gynecology and Obstetrics stage (P<0.0001).
FDG-PET/CT scanning has a high diagnostic value in differentiating between malignant and benign tumors, and a low diagnostic value in differentiating between borderline and benign tumors.

0 Bookmarks
 · 
182 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) is a useful technique for acquiring both glucose metabolic and anatomic imaging data using a single device in a single diagnostic session, and has opened up a new field of clinical oncologic imaging. FDG-PET/CT has been used successfully for the staging, treatment optimization, re-staging, therapy monitoring, and prognostication of uterine and ovarian cancers as well as various malignant tumors. The present review discusses the current role of FDG-PET/CT in the management of gynecologic malignancies, focusing on its usefulness and limitations for imaging such patients.
    Japanese journal of radiology 04/2014; · 0.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study assessed the prognostic value of pre-operative 2-[(18)F] fluoro-2-deoxy-D-glucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), in patients with epithelial ovarian cancer.
    European journal of nuclear medicine and molecular imaging 05/2014; · 5.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A correct diagnosis of any adnexal mass is essential to triage women to appropriate treatment pathways. Several imaging techniques are available that may be used to provide an assessment of a mass before treatment, such as transvaginal ultrasonography, magnetic resonance imaging, computed tomography, and positron emission tomography combined with computed tomography. In this chapter, we focus in depth on the role of transvaginal ultrasonography, as current evidence suggests it is the most appropriate initial imaging investigation to identify and characterise any mass if present in women suspected of having adnexal pathology. Subjective assessment by an experienced ultrasound examiner is the optimal approach to diagnose masses, followed by risk models and rules developed by the International Ovarian Tumor Analysis study. A group of tumours has proven difficult to classify with transvaginal ultrasound, and remain a diagnostic challenge for which accurate second-stage tests would be of value. Some studies suggest that magnetic resonance imaging (MRI), compared with other imaging modalities, may play a role in the assessment of this cohort of ‘difficult to classify’ adnexal masses. These studies, however, did not report quality of transvaginal ultrasonography (i.e. experience level of the examiner) and lacked uniformity in describing the criteria used to define such ‘difficult’ masses. On the basis of standardised terminology developed by the International Ovarian Tumor Analysis study to describe adnexal masses, as well as prediction models and rules developed in the course of the study, we propose new criteria that we can use to clearly define complex or ‘difficult to classify’ adnexal masses to focus the role for second-line imaging tests, such as conventional magnetic resonance imaging combined with dynamic contrast-enhanced or diffusion-weighted sequences on masses where further tests other than ultrasonography would be of value.
    Best practice & research. Clinical obstetrics & gynaecology 01/2014; · 1.87 Impact Factor